Daily brief   for adults 50+ Inscreva-se AM & PM email
50 Plus HubEverything for Everyone 50+
Customize My age is in the: 50s 60s 70s 80+ Text size Idioma
‹ Back to Breaking News
health50+

Researchers Develop Experimental Laser Heat Treatment for Macular Degeneration

Thursday, July 16, 2026 · 1 sources

A new experimental treatment uses near-infrared light to heat tissue at the back of the eye, potentially stopping blindness before it starts. The treatment aims to help people with dry age-related macular degeneration, a leading cause of blindness in older adults.

Researchers at Aalto University have discovered a way to gently heat tissue at the back of the eye using near-infrared light. This triggers the cells' natural cleanup and repair systems before major damage occurs. The treatment is experimental and offers hope for millions of people with dry age-related macular degeneration. Dry age-related macular degeneration is one of the leading causes of blindness in older adults. The new treatment could potentially stop blindness before it starts by targeting the condition in its early stages.

The 50+ takeaway: May help prevent blindness in older adults.

Go Deeper

What is dry age-related macular degeneration?

Dry age-related macular degeneration is a condition that causes blindness in older adults. It is one of the leading causes of blindness in this age group.

How does the new treatment work?

The new treatment uses near-infrared light to gently heat tissue at the back of the eye. This triggers the cells' natural cleanup and repair systems before major damage occurs.

Who developed the new treatment?

Researchers at Aalto University developed the new experimental treatment.

Is the treatment available to the public?

The treatment is still experimental and not yet available to the public. Further research is needed to determine its effectiveness and safety.

What are the potential benefits of the new treatment?

The potential benefits of the new treatment include stopping blindness before it starts and improving the quality of life for people with dry age-related macular degeneration.